Source: NEJM RENAAL Trial Key Points1. Losartan was found to have significant reno-protective role in patients with type II diabetes and nephropathy.2. Losartan did not affect mortality in this patient population.3. Proteinuria significant improved in patients taking losartan compared to placebo.4. The IDNT trial tested irbesartan and reported similar renoprotective role in diabetic nephropathy. Guideline Recommendations based on RENAAL Trial: The..